Bliss GVS Pharma — 360° view

Bliss GVS Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹313 crore and net profit of ₹53 crore for the September 2026 quarter.

Bliss GVS Pharma (NSE: BLISSGVS-BE) closed at ₹640.55 on 20 Nov 2026. Its market capitalisation is ₹6,814 crore and it trades at 41.9 times earnings.

Share price
₹640.55 (20 Nov 2026)
Market cap
₹6,814 Cr (20 Nov 2026)
P/E
41.90 (20 Nov 2026)
Revenue
₹313 Cr (September 2026 quarter)
Net profit
₹53 Cr (September 2026 quarter)
ROCE
16.9% (FY26)
ROE
11.8% (FY26)
Book value
₹121 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹739.90 / ₹443.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BLISSGVS-BE

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.